Oral anabolic androgenic steroid
Methandienone (Dianabol)
Methandienone (Dianabol) after one dose: 50% at ~4.5 h, 25% at 9 h, 12.5% at 13.5 h.
Drawn from the half-life in the app's model, ~4.5 h. The model's figures
- Compound
- Methandienone (Dianabol)
- Symbol
- DBL
- Family
- Other steroids
- Parts
- 13
- References
- 23
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
- 1World Anti-Doping Agency, 2026
- 2US Drug Enforcement Administration
- 3International Programme on Chemical Safety, 1998
- 4Freed et al., 1975
- 5Misuse of Drugs Act 1971, 1971
- 6Hervey et al., 1976
- 7Hervey et al., 1981
- 8Freed et al., 1975
- 9Godsland et al., 1986
- 10Rosenfeld et al., 2011
- 11Girgis et al., 2014
- 12Poomthavorn et al., 2009
Methandienone, also written metandienone and methandrostenolone, is an anabolic steroid with the chemical name 17beta-hydroxy-17alpha-methylandrosta-1,4-dien-3-one.3 Dianabol is a brand name for it: a 1975 trial in the British Journal of Sports Medicine is titled as a trial of "methandienone (Dianabol, CIBA)".4 The International Programme on Chemical Safety (IPCS) monograph on methandienone, written by R. E. Ferner in 1994, states that it is harmonised with the group monograph on anabolic steroids (PIM G007).3
The WADA 2026 Prohibited List names metandienone, when administered exogenously, in class S1.1, anabolic androgenic steroids, which is prohibited at all times, in and out of competition.1 In the US, 21 CFR 1308.13 lists methandienone among the anabolic steroids in Schedule III.2 In the UK, Part III of Schedule 2 to the Misuse of Drugs Act 1971, headed Class C drugs, lists methandienone.5
Two double-blind crossover trials of 100 mg a day for 6 weeks in athletic men, by Hervey and colleagues in 1976 and 1981, reported weight gain on methandienone.6,7 Strength and performance did not differ significantly between drug and placebo in the 1976 trial, and increased significantly on the drug but not on placebo in the 1981 trial.6,7
Reported adverse findings include a significant rise in systolic blood pressure and three withdrawals in a 13-person trial, impaired glucose tolerance with a markedly increased insulin response in 9 patients, and single case reports of cholestatic jaundice, hepatitis and, in two children, virilization (with adrenal suppression in the boy), three of them in people also taking other drugs (stanozolol; anti-estrogens and diuretics; cyproheptadine).8,9,10,11,12
How it works
Reported in people
The IPCS monograph states that anabolic steroids bind to specific receptors present especially in reproductive tissue, muscle and fat, and that in practice all agents of the class possess both anabolic and androgenic properties to some degree.3 The same monograph states: "There is no clear evidence that anabolic steroids enhance overall athletic performance", citing Elashoff and colleagues, 1991.3 In the 1981 repeat, body potassium rose by 436 mmol (+/- SEM 41) and body nitrogen by 255 g (+/- 69) with a weight gain of 2.3 kg (+/- 0.4).7 The authors wrote that these increases were too large in proportion to the weight gain to be attributed to gain of normal muscle or other lean tissue, and implied "gain of nitrogen-rich, phosphate-poor substance".7
In tissue preparations and metabolism studies
In a 1984 study by Saartok and colleagues, steroids were tested as competitors for binding of [3H]methyltrienolone to the androgen receptor in rat and rabbit skeletal muscle and in rat prostate.13 Binding of methanedienone was weak, with relative binding affinity values less than 0.05.13 In 2012, Parr and colleagues reported that in enzyme tests the human mitochondrial enzymes CYP11B1 and CYP11B2 were capable of metabolizing metandienone, and that analysis of urine after oral administration of metandienone to one volunteer and of its rearrangement product NorMD to another confirmed their contribution.14
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4.5 h
- Bioavailability
- 95%
- Typical dose
- 10–50 mg/day
- Route
- Oral
- Time to peak
- ~1.5 h
The app lists a half-life of ~4.5 hours for methandienone. In its general section on anabolic steroids, the IPCS monograph states that "the elimination half-life from plasma is very short" and prints no number.3 That sentence sits in a passage that goes on to say the duration of biological effects is "determined almost entirely by the rate of absorption from subcutaneous or intramuscular depots, and on the de-esterification which precedes it".3
| Parameter | App value | Source figure |
|---|---|---|
| Half-life | ~4.5 hours | In its general section on anabolic steroids, the IPCS monograph states that the elimination half-life from plasma is "very short" and prints no number.3 |
| Bioavailability (oral) | ~95% | The IPCS monograph prints no percentage; it states that oral dosing involves extensive first-pass hepatic metabolism for all anabolic steroids except those substituted at the 17-alpha position.3 |
| Time to peak | ~1.5 hours | The IPCS monograph prints no time to peak; it states that absorption after oral dosing is rapid for testosterone and probably for other anabolic steroids.3 |
| Route | Oral | Given by mouth at 10 to 50 mg daily in a 1999 case report, and by oral administration in a 1991 excretion study.15,16 |
| Typical dose | 10 to 50 mg/day | Doses in the trials below ran from 2.5 mg daily to 100 mg/day.17,6 |
| Markers to monitor | Liver enzymes, lipids, hematocrit | The IPCS monograph lists hepatic function tests, cholesterol concentration and a full blood count among tests relevant in the investigation of chronic anabolic steroid abuse.3 |
After oral administration of metandienone to male volunteers, Schänzer, Geyer and Donike reported in 1991 that unconjugated metabolites reached maximum excretion rates between 4 and 12 h after administration and conjugated metabolites III, IV and V between 12 and 34 h.16 These are timings of metabolites in urine, not a concentration curve of methandienone in plasma.16 In 2006, Schänzer and colleagues reported a new long-term metabolite in urine up to 19 days after a single dose of 5 mg.18
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Freed and colleagues, 19758 | Double-blind crossover; no sponsor stated in the PubMed record | 13 experienced male weightlifters on high-protein diets and regular exercise | 10 or 25 mg/day; length not stated | Improvements significantly greater than on placebo; body weight rose, seemingly with water retention; systolic blood pressure rose significantly; three men withdrew because of side effects, which disappeared after the drug was stopped. |
| Hervey and colleagues, 19766 | Double-blind crossover; no sponsor stated in the PubMed record | 11 athletic men during weight-training | 100 mg/day for 6 weeks | Against placebo, weight rose a mean 3.3 kg (+/- 0.6) and body potassium 420 mmol (+/- 68), with the weight gain confined to the lean part of the body (authors: may be intracellular fluid); strength and performance did not differ significantly; plasma cortisol rose and plasma testosterone fell. |
| Hervey and colleagues, 19817 | Double-blind crossover, 6-week periods separated by 6 weeks; no sponsor stated in the PubMed record | 7 male weight-lifters in regular training | 100 mg/day, 6 weeks | Body weight, potassium, nitrogen, muscle size, leg performance and strength increased significantly on the drug but not on placebo; weight gain 2.3 kg (+/- 0.4). |
| Chesnut and colleagues, 197719 | Double-blind placebo-controlled; no sponsor stated in the PubMed record | 26 postmenopausal women with osteoporosis; 16 completed (10 treated, 6 placebo) | Dose not stated; 26 months | Total body calcium rose 2% on methandrostenolone and fell 3% on placebo in completers (p less than 0.01 for the difference); the authors wrote that the data strongly suggest long-term use prevented bone loss and that a rise above initial values is "less certain". |
| Aloia and colleagues, 198120 | Double-blind, randomized, parallel, placebo-controlled; no sponsor stated in the PubMed record | People with osteoporosis; number not stated | Dose not stated; 24 months | Total body potassium rose in the treated group, mainly in the first 6 months; bone mass did not change significantly except total body calcium at 6 months, +11 g against -6 g on placebo (p = .05). |
| Inkovaara and colleagues, 198317 | Double-blind placebo-controlled, all combinations of three agents; no sponsor stated in the PubMed record | 327 people over 65 (57 men), mean age 79.5 | Methandienone 2.5 mg daily, with or without calcium carbonate 3 g and vitamin D3 1000 iu, for 9 months | Fractures more frequent on placebo, not significantly; coronary mortality higher among those on all three agents; with two treatments the increase in coronary deaths was not significant, but pooling the two-treatment groups against those on one or neither showed a significant increase, most (P less than 0.001) for vitamin D3 with methandienone; authors: methandienone reduced osteoporotic activity and increased muscular mass most effectively. |
| Godsland and colleagues, 19869 | Patients off and on treatment; no sponsor stated in the PubMed record | 9 patients | Dose and length not stated | On treatment: markedly increased insulin response with impaired glucose tolerance; fasting glucose and insulin significantly reduced; sensitivity of glucose disposal to insulin reduced by a factor of 4. |
Deeper analysis: Hervey and colleagues, 1976
Hervey and colleagues (Lancet, 1976) gave methandienone to 11 athletic men during a course of weight-training, in a double-blind, crossover experiment at 100 mg/day for 6 weeks.6 Compared with the placebo period, the men gained weight and accumulated potassium, the weight gain was confined to the lean part of the body, and the muscles increased in size, while strength and performance improved over each training period but not significantly differently on drug and placebo.6 The authors wrote that the weight and body-composition changes "may alternatively have been caused by an increase in intracellular fluid, and the question of anabolic action therefore remains open".6 The PubMed record gives no sponsor, affiliations or adverse events.6
Deeper analysis: Hervey and colleagues, 1981
Hervey and colleagues (Clinical Science, 1981) repeated the trial in seven male weight-lifters in regular training, adding measurements of total body nitrogen, with 100 mg of methandienone a day given alternately with placebo in 6-week periods separated by 6 weeks.7 In the repeat, body weight, potassium and nitrogen, muscle size, and leg performance and strength increased significantly on the drug but not on placebo.7 They wrote that the finding of increased body nitrogen suggested the weight gain was "not only intracellular fluid", and concluded that "Although this action of methandienone might be described as anabolic, the weight gain produced is not normal muscle".7 The PubMed record gives no sponsor, affiliations or adverse events.7
Deeper analysis: Freed and colleagues, 1975
Freed and colleagues (British Medical Journal, 1975) ran a double-blind crossover trial of methandienone 10 or 25 mg/day in 13 experienced male weightlifters taking high-protein diets and regular exercise, to see whether the drug improved athletic performance.8 Improvements were significantly greater on methandienone than on placebo, body weights rose, and systolic blood pressure rose significantly.8 The authors reported that methandienone caused many side effects, that three men had to withdraw because of them, and that all side effects disappeared after the drug was stopped.8 The PubMed record gives no sponsor, affiliations or stated limitations.8
Deeper analysis: methandrostenolone in osteoporosis, 1977 and 1981
Chesnut and colleagues (Metabolism, 1977) ran a 26-month double-blind study in 13 treated and 13 placebo postmenopausal women with osteoporosis, with total body calcium measured by neutron activation analysis as the main outcome.19 Sixteen completed the study (10 treated, 6 placebo); in those who dropped out, total body calcium changes through the time of dropout were similar to those in completers.19 Total body calcium increased 2% in the treated group and decreased 3% in the placebo group, and the authors wrote that "these data strongly suggest that long-term use of methandrostenolone in postmenopausal osteoporosis prevented bone loss; the possibility that it increased bone mass above initial values is less certain".19 Aloia and colleagues (Metabolism, 1981) ran a 24-month double-blind, randomized, parallel comparison with placebo and reported no significant changes in bone mass except a 6-month total body calcium difference of +11 g against -6 g (p = .05).20 They wrote that if methandrostenolone can produce an increment in bone mass in osteoporosis, "it was not readily observable with the sensitivity of the techniques employed in this study".20 Neither PubMed record states a sponsor or lists author affiliations, and neither gives a dose.19,20
Deeper analysis: Inkovaara and colleagues, 1983
Inkovaara and colleagues (Age and Ageing, 1983) gave 327 people over 65 (57 men, mean age 79.5) all possible combinations of calcium carbonate 3 g, vitamin D3 1000 iu, methandienone 2.5 mg and placebos daily for 9 months.17 The higher incidence of bone fractures in the placebo group was not significant, and, among the serum measures followed, the greatest changes occurred with methandienone, which the authors wrote "thus reduced osteoporotic activity and increased the muscular mass most effectively", while calcium carbonate "had the poorest effect".17 They described it as surprising that "coronary mortality was higher among those taking all three active substances".17 With two treatments the increase was not significant, but a pooled comparison showed a significant increase in coronary deaths, most significant (P less than 0.001) in those receiving vitamin D3 and methandienone.17 The PubMed record gives no sponsor, affiliations or stated limitations.17
Doses reported in studies and case reports
The doses below are those the sources report, and "not stated" means the PubMed record gives none; they are not recommendations.8,6
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Freed and colleagues, 19758 | 10 or 25 mg/day | Per day; dosing times not stated | Not stated |
| Hervey and colleagues, 19766 | 100 mg/day | Per day; dosing times not stated | 6 weeks |
| Hervey and colleagues, 19817 | 100 mg/day | Per day, alternating with placebo | 6 weeks per period, 6 weeks apart |
| Inkovaara and colleagues, 198317 | 2.5 mg | Daily | 9 months |
| Schänzer and colleagues, 199116 | 40 mg | Not stated | Excretion followed after administration; length not stated |
| Schänzer and colleagues, 200618 | 5 mg | Single dose | Metabolite detected in urine up to 19 days after the dose |
| Habscheid and colleagues, 1999 (case report)15 | 10 to 50 mg daily by mouth, with stanozolol 50 mg intramuscularly every other day | Daily | 80 days |
Side effects reported
In the 1975 trial of 13 weightlifters, three men withdrew because of side effects, systolic blood pressure rose significantly and body weights rose, which seemed to be associated with water retention.8 In the 1983 trial of people over 65, coronary mortality was higher among those taking all three active substances, including methandienone 2.5 mg daily.17 The IPCS monograph states that there is no serious risk from acute poisoning but that chronic use can cause harm.3 For orally active 17-alpha substituted anabolic steroids it states that they can cause abnormalities of hepatic function, shown as elevated hepatic enzyme activity in biochemical tests and sometimes as overt jaundice, and that peliosis hepatis has been associated with anabolic steroid use.3 For chronic use of the class it lists, among other effects, virilization in women, prostatic hypertrophy, impotence and azoospermia in men, acne, abnormal lipids, premature cardiovascular disease, abnormal glucose tolerance and psychiatric disturbances, and it notes reports of angiosarcoma and of a case of hepatocellular carcinoma in an anabolic steroid user.3
Case reports
Rosenfeld and colleagues (Journal of Medical Case Reports, 2011) described a 50-year-old man who presented with a six week history of abdominal pain, anorexia and weight loss after an eight week cycle of methandrostenolone use.10 Imaging was consistent with acute pancreatitis, a liver biopsy with intra-hepatic cholestasis and a kidney biopsy with acute tubular necrosis, and bilirubin was 922 μmol/L at presentation.10 Girgis and colleagues (Endocrine Practice, 2014) described a 35-year-old amateur body-builder who developed acute hepatitis with accompanying fever several weeks after starting high-dose methandrostenolone, taken with anti-estrogen drugs and diuretics.11 Habscheid and colleagues (Deutsche Medizinische Wochenschrift, 1999) described a 28-year-old body builder with jaundice after 80 days of metandienone and intramuscular stanozolol, whose serum bilirubin rose to a maximum of 77.9 mg/dl with renal failure (creatinine 4.2 mg/dl), and who improved as ursodeoxycholic acid was given.15 Poomthavorn and colleagues (2009) reported a 4-year-old boy and a 2-year-old girl given an off-label appetite stimulant syrup that contained cyproheptadine and methandienone.12 The authors wrote that methandienone undoubtedly caused precocious virilization in both children, that both cyproheptadine and methandienone were responsible for severe adrenal suppression in the boy, and that stopping the syrup led to partial regression of virilization in both and normalization of adrenal reserve function in the boy.12
Deaths with metandienone among several substances
Lehmann and colleagues (Forensic Science International, 2019) described a 34-year-old man who collapsed and died minutes after being found breathless; femoral blood held about 1 μg/L clenbuterol, about 56 μg/L stanozolol and about 8 μg/L metandienone, with trenbolone below the limit of quantification.21 Autopsy showed left ventricular hypertrophy and a right coronary artery with a small lumen, 3 mm in diameter; urine also tested positive for boldenone, clomiphene, drostanolone and trenbolone, with indications of testosterone or testosterone prohormones.21 The authors wrote that it can be assumed that the long-term consumption of anabolic androgen steroids caused apparently pathological changes of the heart, and that the combination of anatomical risk factors (small-lumen coronary artery, ventricular hypertrophy) and substance-induced risk factors led to the fatal cardiovascular failure.21 Darke and colleagues (Journal of Forensic Sciences, 2014) reviewed 24 anabolic-androgenic steroid positive cases at the New South Wales Department of Forensic Medicine, 1995 to 2012, and reported metabolites of methandienone in 20.8%; substances other than steroids were detected in 23 of the 24 cases.22
Bloodwork and markers
Sources in this part
The app lists liver enzymes, lipids and hematocrit as markers to monitor for methandienone. The IPCS monograph lists a full blood count, electrolytes and renal function tests, hepatic function tests, testosterone, luteinizing hormone, prostate-related markers, blood glucose concentration and cholesterol concentration as tests relevant in the investigation of chronic anabolic steroid abuse.3 It states that anabolic androgens stimulate erythropoiesis, and that hypercholesterolaemia with a fall in high density lipoprotein cholesterol has been reported.3
Regulatory and anti-doping status
The WADA 2026 Prohibited List, in effect from 1 January 2026, names metandienone under S1.1, anabolic androgenic steroids, when administered exogenously.1 Class S1 is prohibited at all times, in and out of competition, and all prohibited substances in the class are non-specified substances.1 In the US, 21 CFR 1308.13, the Drug Enforcement Administration's Schedule III list, includes methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one) in its paragraph on anabolic steroids.2 In the UK, the Misuse of Drugs Act 1971 lists methandienone in Part III of Schedule 2, Class C drugs.5 The IPCS monograph, citing the ABPI Data Sheet Compendium (1993), states that the only legitimate therapeutic indications for anabolic steroids are replacement of male sex steroids in men who have androgen deficiency and certain rare forms of aplastic anaemia.3
What is not known
The IPCS monograph prints no half-life, bioavailability or time-to-peak figure for methandienone, so the app's figures of ~4.5 hours, ~95% and ~1.5 hours have no matching figure in it.3 The monograph's statement that the elimination half-life from plasma is very short comes from its general section on anabolic steroids, in a passage whose next sentence concerns absorption from subcutaneous or intramuscular depots.3 The PubMed records of the trials give no sponsor statement and no author affiliations, the full papers were not read, and the osteoporosis trials and the 1986 glucose study give no dose.8,6,19,20,9 The trials with a stated number enrolled between 7 and 327 people, and the longest described here ran 26 months.7,17,19 No aromatization measurement for methandienone is reported in the studies summarised here, although the app lists aromatizes among its interaction flags for it.
Frequently asked questions
Sources in this part
- 1World Anti-Doping Agency, 2026
- 2US Drug Enforcement Administration
- 3International Programme on Chemical Safety, 1998
- 4Freed et al., 1975
- 5Misuse of Drugs Act 1971, 1971
- 6Hervey et al., 1976
- 7Hervey et al., 1981
- 8Freed et al., 1975
- 9Godsland et al., 1986
- 10Rosenfeld et al., 2011
- 11Girgis et al., 2014
- 12Poomthavorn et al., 2009
- 13Saartok et al., 1984
- 16Schänzer W, 1991
- 17Inkovaara et al., 1983
- 18Schänzer W, 2006
- 19Chesnut et al., 1977
- 23Steff et al., 2025
What is Dianabol?
What is the half-life of Dianabol?
The app lists a half-life of ~4.5 hours for methandienone. In its general section on anabolic steroids, the IPCS monograph states that "the elimination half-life from plasma is very short" and prints no number.3 In a 1991 excretion study after oral administration, unconjugated metabolites reached maximum excretion rates between 4 and 12 h and conjugated metabolites III, IV and V between 12 and 34 h; these are urinary excretion timings, not a plasma half-life.16
Is Dianabol banned by WADA?
Is Dianabol a controlled substance?
How long can methandienone be detected in urine?
Did Dianabol increase strength in trials?
Two double-blind crossover trials of 100 mg a day for 6 weeks gave different strength results.6,7 In 1976 strength and performance improved over each training period but not significantly differently on drug and placebo, and in 1981 leg performance and strength increased significantly on the drug but not during the placebo period.6,7 The 1981 authors wrote that "Although this action of methandienone might be described as anabolic, the weight gain produced is not normal muscle". In the 1975 trial of 13 weightlifters, improvements were significantly greater on methandienone than on placebo, and the PubMed record does not say what was measured.7
What side effects have been reported with Dianabol?
In a 13-person trial, systolic blood pressure rose significantly and three men withdrew because of side effects, which disappeared after the drug was stopped.8 Single case reports describe cholestatic jaundice with acute kidney injury and acute pancreatitis, acute hepatitis with fever (also on anti-estrogens and diuretics), and, in two children given a syrup that also contained cyproheptadine, virilization, with adrenal suppression in the boy.10,11,12 In a 1983 trial of people over 65, coronary mortality was higher among those taking all three active substances, including methandienone 2.5 mg daily.17
Does methandienone bind the androgen receptor?
In rat and rabbit skeletal muscle and rat prostate preparations, binding of methanedienone to the androgen receptor was weak, with relative binding affinity values less than 0.05.13
More in Other steroids
References
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026, in effect 1 January 2026. WADA Prohibited List 2026
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. eCFR 21 CFR 1308.13
- International Programme on Chemical Safety. Methandienone. Poisons Information Monograph 905. Author: Ferner RE, 1994; editor Ruse M, 1998. IPCS monograph PIM 905
- Freed DL, Banks AJ. A double-blind crossover trial of methandienone (Dianabol, CIBA) in moderate dosage on highly trained experienced athletes. Br J Sports Med 1975. PMID 1102048
- Misuse of Drugs Act 1971, Schedule 2, Part III (Class C drugs). legislation.gov.uk. UK Misuse of Drugs Act 1971, Schedule 2
- Hervey GR, Hutchinson I, Knibbs AV, et al. "Anabolic" effects of methandienone in men undergoing athletic training. Lancet 1976. PMID 61389
- Hervey GR, Knibbs AV, Burkinshaw L, et al. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin Sci (Lond) 1981. PMID 7018798
- Freed DL, Banks AJ, Longson D, et al. Anabolic steroids in athelics: crossover double-blind trial on weightlifters. Br Med J 1975. PMID 125133
- Godsland IF, Shennan NM, Wynn V. Insulin action and dynamics modelled in patients taking the anabolic steroid methandienone (Dianabol). Clin Sci (Lond) 1986. PMID 3539458
- Rosenfeld GA, Chang A, Poulin M, et al. Cholestatic jaundice, acute kidney injury and acute pancreatitis secondary to the recreational use of methandrostenolone: a case report. J Med Case Rep 2011. PMID 21470406
- Girgis CM, Kuo I, Handelsman DJ. Acute hepatitis and fevers in an amateur body-builder: a new complication of synthetic androgen abuse? Endocr Pract 2014. PMID 24641932
- Poomthavorn P, Mahachoklertwattana P, Khlairit P. Childhood virilization and adrenal suppression after ingestion of methandienone and cyproheptadine. J Pediatr Endocrinol Metab 2009. PMID 19618666
- Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology 1984. PMID 6539197
- Parr MK, Zöllner A, Fusshöller G, et al. Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - insights from metandienone metabolism. Toxicol Lett 2012. PMID 22885098
- Habscheid W, Abele U, Dahm HH. Severe cholestasis with kidney failure from anabolic steroids in a body builder. Dtsch Med Wochenschr 1999. PMID 10506840
- Schänzer W, Geyer H, Donike M. Metabolism of metandienone in man: identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas chromatographic-mass spectrometric identification of bis-hydroxylated metabolites. J Steroid Biochem Mol Biol 1991. PMID 2031859
- Inkovaara J, Gothoni G, Halttula R, et al. Calcium, vitamin D and anabolic steroid in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age Ageing 1983. PMID 6346829
- Schänzer W, Geyer H, Fusshöller G, et al. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Commun Mass Spectrom 2006. PMID 16804957
- Chesnut CH 3rd, Nelp WB, Baylink DJ, et al. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass. Metabolism 1977. PMID 319322
- Aloia JF, Kapoor A, Vaswani A, et al. Changes in body composition following therapy of osteoporosis with methandrostenolone. Metabolism 1981. PMID 7026971
- Lehmann S, Thomas A, Schiwy-Bochat KH, et al. Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). Forensic Sci Int 2019. PMID 31499423
- Darke S, Torok M, Duflou J. Sudden or unnatural deaths involving anabolic-androgenic steroids. J Forensic Sci 2014. PMID 24611438
- Steff J, Molaioni F, Schlörer N, et al. Reduced and rearranged metabolite structures after metandienone administration: New promising metabolites for potential long-term detection. J Steroid Biochem Mol Biol 2025. PMID 40473058